1 earning revenue on a royalty deal the CEO got screwed on, APAS seeking FDA approval but still under development with Hettich, and the other is a pipe dream (w/ huge potential as does APAS) that may take years to come into fruition.That's why.
LBT has a great technology and we'll really see it moving when it gets FDA approval and then a distribution deal. This is a long term, not short term buy.
